# Endocannabinoid System: Cannabis Anxiety Relief Study Insights > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/endocannabinoid-system-cannabis-anxiety-relief/ > **Published:** 2026-03-15T14:17:13-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:07:16-04:00 > **Clinical Summary:** Explore the endocannabinoid system cannabis anxiety relief study showing varied effects of flower and edible products on anxiety symptoms over 30 days. --- #### Clinical Takeaway Cannabis use for anxiety showed different daily effects depending on whether people used flower or edible products, with THC and CBD combinations producing varying results across product types. While some formulations were associated with short-term anxiety reductions, the effects were not uniform and differed between immediate and longer-term outcomes over 30 days. ### #8 Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products. **Citation:** Rosa Luiza et al. *Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.* International journal of environmental research and public health. 2026. PMID: 41752306. **Study type:** Journal Article, Randomized Controlled Trial  |  **Topic area:** Cannabidiol  |  **CED Score:** 11 Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2 Why This Matters This study provides longitudinal evidence on whether cannabis actually reduces anxiety symptoms in real-world use, addressing a critical gap between patient-reported motivations for use and measurable clinical outcomes. The differential effects between flower and edible formulations have direct implications for clinical counseling and patient selection, as product type appears to influence both acute and sustained anxiolytic responses. These findings inform evidence-based recommendations for cannabis as a therapeutic intervention in [anxiety management](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/), moving beyond anecdotal reports to quantifiable daily symptom trajectories. **Quality Gate Alerts:** - Preclinical only **Abstract:** Research shows that delta-9-tetrahydrocannabinol (THC) is linked to increased anxiety, while cannabidiol (CBD) may have anxiolytic effects. Cannabis use is often driven by coping with anxiety, though its daily impact on anxiety remains unclear. This study examined daily associations between cannabis use and anxiety across 30 days in adults who wanted to use cannabis for anxiety relief. Participants (N = 345) used flower or edible products ad libitum and were randomly assigned to groups by product type (CBD, THC, or THC + CBD). Each day, participants reported cannabis use in the past 24 h and rated their anxiety. Linear mixed-effects models tested whether anxiety changed over time, differed by cannabinoid group, and varied with use. Anxiety significantly decreased over the study period in both flower and edibles groups. In the flower group, THC + CBD and CBD products had greater decreases in anxiety (39.5% and 34.8%, respectively) compared to THC products (7.8%). In the edibles group, when participants used CBD products, this was associated with a 24.9% reduction in anxiety over the 30 days. Findings underscore the importance of distinguishing cannabis effects by product type and cannabinoid composition and suggest that CBD-dominant edibles were associated with less anxiety over time in this naturalistic study. Clinical Perspective This longitudinal study offers valuable real-world data on how different cannabis product formats may differentially affect anxiety symptoms over time, addressing a significant gap since most anxiety research relies on cross-sectional designs or laboratory settings. The finding that flower and edible products show varying daily and sustained effects on anxiety is clinically relevant, though important confounders warrant consideration: the study does not appear to control for THC-to-CBD ratios, individual cannabinoid sensitivity, concurrent medications, or comorbid conditions that commonly accompany anxiety disorders. Additionally, self-selected participants motivated to use cannabis for anxiety may not represent patients with treatment-resistant anxiety or those in whom cannabis might exacerbate symptoms, and the ad libitum dosing approach, while ecologically valid, limits our ability to identify optimal dosing thresholds. When counseling patients about cannabis for anxiety, clinicians should recognize that product type may matter, but individual response remains highly variable and should be monitored closely during the first 30 days of use, with particular attention  |   |  Further Reading Cannabis Policy Wire[Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://cedclinic.com/temporary-scheduling-novel-benzodiazepines-bromazolam-update/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[AM Policy Update: March 11, 2026](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/41752306/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12941097/)[DOI ↗](https://doi.org/10.3390/ijerph23020224) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System Cannabis Anxiety Treatment Evidence](https://cedclinic.com/cbd-dominant-cannabis-anxiety-relief-study/) Review evidence on how the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) mediates cannabis effects for anxiety treatment. [Read More](https://cedclinic.com/cbd-dominant-cannabis-anxiety-relief-study/) [endocannabinoid system: Cannabis Reduces Anxiety Long-Term](https://cedclinic.com/cbd-anxiolytic-benefits-anxiety-relief/) Explore long-term anxiety reduction linked to cannabis use and endocannabinoid system interactions. [Explore Insights](https://cedclinic.com/cbd-anxiolytic-benefits-anxiety-relief/) [endocannabinoid system: Cannabis Anxiety Research 2026](https://cedclinic.com/endocannabinoid-system-cannabis-anxiety-research/) Latest 2026 research updates on [cannabis and anxiety](https://cedclinic.com/dose-dependence-delta-9-thc-place-conditioning/) focusing on the endocannabinoid system. [Discover Research](https://cedclinic.com/endocannabinoid-system-cannabis-anxiety-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Endocannabinoid%20System%3A%20Cannabis%20Anxiety%20Relief%20Study%20Insights&url=https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-cannabis-anxiety-relief%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-cannabis-anxiety-relief%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Endocannabinoid%20System%3A%20Cannabis%20Anxiety%20Relief%20Study%20Insights%20https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-cannabis-anxiety-relief%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).